Assessment of Needs
This case-based panel webinar will discuss the most challenging issues in drug therapy and anticipated barriers to the implementation of long-acting injectable preexposure prophylaxis (PrEP), which was approved by the US Food and Drug Administration in December 2021. This webinar will review key aspects of its clinical pharmacology and the challenges in the diagnosis of HIV in patients on long-acting PrEP.
This webinar is part 2 of a 2-part webinar series on the updated PrEP guidelines. Part 1 provides a summary of the Latest Update to the PrEP Guidelines.
At the end of this webinar, participants will be able to:
- Describe the data and key points that support the use of long-acting injectable cabotegravir (CAB-LA) as preexposure prophylaxis PrEP
- Identify how to address the challenges of implementing CAB-LA in the clinic
- Monitor for drug-drug interactions with cabotegravir
- Manage long-acting PrEP in the setting of pregnancy
- Describe difficulties in interpreting HIV diagnostic tests results in patients on CAB-LA
- Initiate anti-retroviral therapy in people with HIV who had prior exposure to CAB-LA
Who Should Attend
This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.
Individual registration is required in order to receive CME credit or a certificate of participation.
Registration closes on Tuesday, June 28, 2022, 9:00 AM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at email@example.com or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.
The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
The IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies information for the presenter and planners/reviewers are below and in the presentation. All relevant financial relationships with ineligible companies have been mitigated.
Dr Castillo-Mancilla has received grants/grant pending paid to his institution from Gilead Sciences, Inc. (Updated 01/17/22)
Dr Kelley has received grants/grants pending paid to her institution from Moderna, Inc., Novavax, Humanigen, Gilead Sciences, Inc., and ViiV Healthcare. (Updated 02/22/22)
Dr Scarsi has received grant/grants pending paid to her institution from Organon LLC. (Updated 01/28/22)
Dr Scott has no financial relationships with ineligible companies to disclose. (Updated 02/22/22)
Planner/Reviewer 1 has no relevant financial relationships with ineligible companies to disclose. (Updated 02/08/22)
Planner/Reviewer 2 has no relevant financial relationships with ineligible companies to disclose. (Updated 02/08/22)
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Point
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.5 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California (Provider # 14692), the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.5 contact hours (0.15 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-22-337-L02-P
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co, Inc.
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at firstname.lastname@example.org or 415-544-9400.